Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada
“Pure Sunfarms is already one of the largest licensed cannabis production facilities in the industry, and we expect completion of the conversion in Q1,” said Dr.
“Pure Sunfarms has delivered to Emerald contracted cannabis shipments that we are selling under the Emerald brand. It is also selling to other LPs, with favourable spot market pricing, as it awaits its packaging sales license to commence direct sales to provincial distributors. Pure Sunfarms continues to implement its plan to be a vertically integrated cannabis producer and marketer.”
Pure Sunfarms has completed conversion of the remainder of Quadrant 3 and is awaiting
All supplemental lighting is operational in Quadrants 2 and 3, and is expected to be operational in Quadrant 4 upon start of production, supporting maximum yields during the lower-daylight winter months. Supplemental lighting will be installed in Quadrant 1, which was completed as per plan earlier this year without supplemental lighting in order to permit immediate production during the summer months when supplemental lighting is not required. Quadrant 1 is expected to resume production by the end of
Please visit http://www.emeraldhealth.ca for more information or contact:
(800) 757 3536 Ext. #5
(800) 757 3536 Ext. #5
Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.
Source: Emerald Health Therapeutics Inc.